Bone Biologics is a publicly traded corporation located in Burlington, MA, and specializes in the development and promotion of orthobiologic products. The company's exclusive platform technology revolves around NELL-1, a synthetic human protein growth factor crucial for normal bone formation. The corporation is currently finalizing crucial animal research and pursuing approval to commence human trials in Australia. It aims to enter the potential $3 billion orthobiologics market upon successful completion of pivotal human studies in the U.S.